Platinum-Sensitive Lung Small Cell Carcinoma

Platinum-Sensitive Lung Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03896503	Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	active not recruiting	Phase 2	104	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT04607954	Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer	active not recruiting	Phase 2	29	Mayo ClinicOTHER	1	Mar 31, 2026	clinicaltrials